Detalhe da pesquisa
1.
Distinct effects on gene expression of chemical and genetic manipulation of the cancer epigenome revealed by a multimodality approach.
Cancer Cell
; 6(4): 361-71, 2004 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-15488759
2.
DNMT1 as a molecular target in a multimodality-resistant phenotype in tumor cells.
Mol Cancer Res
; 6(2): 243-9, 2008 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-18314485
3.
Distinct effects of ionizing radiation on in vivo murine kidney and brain normal tissue gene expression.
Clin Cancer Res
; 12(12): 3823-30, 2006 Jun 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-16778110
4.
BAT3 and SET1A form a complex with CTCFL/BORIS to modulate H3K4 histone dimethylation and gene expression.
Mol Cell Biol
; 28(21): 6720-9, 2008 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-18765639
5.
CTCFL/BORIS is a methylation-independent DNA-binding protein that preferentially binds to the paternal H19 differentially methylated region.
Cancer Res
; 68(14): 5546-51, 2008 Jul 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-18632606
6.
DNA methyltransferase 1 and 3B activate BAG-1 expression via recruitment of CTCFL/BORIS and modulation of promoter histone methylation.
Cancer Res
; 68(8): 2726-35, 2008 Apr 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-18413740
7.
SIRT3 interacts with the daf-16 homolog FOXO3a in the mitochondria, as well as increases FOXO3a dependent gene expression.
Int J Biol Sci
; 4(5): 291-9, 2008 Sep 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-18781224
8.
Thioredoxin and thioredoxin reductase as redox-sensitive molecular targets for cancer therapy.
Curr Pharm Des
; 13(33): 3368-77, 2007.
Artigo
em Inglês
| MEDLINE | ID: mdl-18045191
9.
Redox-sensitive signaling factors as a novel molecular targets for cancer therapy.
Drug Resist Updat
; 8(5): 322-30, 2005 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-16230045
10.
The epigenome as a molecular marker and target.
Cancer
; 104(9): 1789-93, 2005 Nov 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-16149092